


WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a compound of (I)



(I)

wherein

n is 0 to 5;

R¹ is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;


R² and R³ are selected as in a) or b) as below,

a) R² is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted alkyl, and optionally substituted heteroalkyl, -OR⁶, -S(O)_iR⁶, -N(R⁷)R⁸, -N(R⁹)S(O)_iR¹⁰, -C(O)R⁶, -C(O)OR⁶, and -C(O)N(R⁷)R⁸; and R³ is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or

b) R² and R³, together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl ring, optionally substituted heterocyclyl ring, an optionally substituted cycloalkenyl ring;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl optionally substituted heterocyclalkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-N(R^{14})C(O)OR^{15}$, $-R^{12}-S(O)_tR^{15}$ and $-R^{12}-S(O)_tN(R^{14})R^{15}$; R^6 represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R^7 represents H or optionally substituted alkyl; R^8 represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R^9 represents H or optionally substituted alkyl; R^{10} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy; R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R^{14} represents H or optionally substituted alkyl; R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

2. The pharmaceutical composition of claim 1, wherein said compound has a formula (II)



wherein

n is 0 to 2; p is 0 to 2; X is N(R⁷), O, or S(O)_r, where r is 0 to 2;

R¹ is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

R³ is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or

R⁴ selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclylalkyl, -R¹²-OR¹³, -R¹²-N(R¹⁴)R¹⁵, -R¹²-C(O)R¹³, -R¹²-C(O)OR¹⁵, -R¹²-C(O)N(R¹⁴)R¹⁵, -R¹²-N(R¹⁴)C(O)R¹⁵, -R¹²-N(R¹⁴)C(O)OR¹⁵, -R¹²-S(O)_iR¹⁵ and -R¹²-S(O)_iN(R¹⁴)R¹⁵;

each R⁵ independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, -OR²⁰, -S(O)_iR²⁰, -N(R⁷)R²⁰, -N(R⁹)S(O)_iR²⁰, -C(O)R²⁰, and -C(O)OR²⁰;

R⁷ and R⁹ are each independently H or optionally substituted alkyl;

R¹² represents a C₁-C₆ alkyl, C₁-C₆ alkenyl, C₁-C₆alkynyl or C₁-C₆ alkoxy represents H or optionally substituted alkyl;

R¹³ represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R¹⁴ represents H or optionally substituted alkyl;

R¹⁵ represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R²⁰ represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl and where each t is independently 0 to 2.

3. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0; p is 0 to 2; X is $N(R^7)$, O , or $S(O)_r$, where r is 0 to 2;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl optionally substituted heterocyclylalkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-N(R^{14})C(O)OR^{15}$, $-R^{12}-S(O)_tR^{15}$ and $-R^{12}-S(O)_tN(R^{14})R^{15}$;

each R^5 independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-N(R^9)S(O)_tR^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl; and

R^{12} represents a C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl or C_1-C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; and

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

4. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 to 2; p is 0 to 2; X is $N(R^7)$, O , or $S(O)_r$, where r is 0 to 2;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy,

aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, lower alkoxy, and lower aminoalkyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl optionally substituted heterocyclylalkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-N(R^{14})C(O)OR^{15}$, $-R^{12}-S(O)_tR^{15}$ and $-R^{12}-S(O)_tN(R^{14})R^{15}$;

each R^5 independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-N(R^9)S(O)_tR^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{20} is represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

5. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 to 2; p is 0 to 2; X is $N(R^7)$, O , or $S(O)_t$, where r is 0 to 2;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy,

aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-S(O)_tR^{15}$;

each R^5 independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-N(R^9)S(O)_tR^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

6. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 to 2; p is 0 to 2; X is $N(R^7)$, O, or $S(O)_t$, where r is 0 to 2;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, hydroxycarbonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, alkoxy, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; or

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl optionally substituted heterocyclylalkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-N(R^{14})C(O)OR^{15}$, $-R^{12}-S(O)_tR^{15}$ and $-R^{12}-S(O)_tN(R^{14})R^{15}$;

each R^5 independently selected from the group consisting of halo, cyano, nitro, hydroxyl, formyl, hydroxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl and

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

7. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 or 1; p is 1 to 2; X is $N(R^7)$;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, hydroxycarbonyl, optionally substituted alkyl, alkoxy, and aminoalkyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted lower

alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, lower alkoxy, and lower aminoalkyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alky, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-S(O)_tR^{15}$;

each R^5 independently selected from the group consisting of halo, cyano, nitro, hydroxyl, formyl, hydroxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

8. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 or 1; p is 1 to 2; X is $S(O)_r$, where r is 0;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, hydroxycarbonyl, optionally substituted alkyl, alkoxy, and aminoalkyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, lower alkoxy, lower aminoalkyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alky, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-S(O)_tR^{15}$;

each R^5 independently selected from the group consisting of halo, cyano, nitro, hydroxyl, formyl, hydroxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

9. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 or 1; p is 1 to 2; X is O;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, hydroxycarbonyl, optionally substituted alkyl, alkoxy, and aminoalkyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, alkoxy, and lower aminoalkyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, and $-R^{12}-S(O)_tR^{15}$;

each R^5 independently selected from the group consisting of halo, cyano, nitro, hydroxyl, formyl, hydroxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl and

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

10. The pharmaceutical composition of claim 2 of formula (II) wherein;

n is 0 or 1; p is 1 to 2; X is $S(O)_r$, where r is 2;

R^1 is each independently selected from the group consisting of halo, pseudohalo, cyano, nitro, hydroxyl, hydroxycarbonyl, optionally substituted alkyl, alkoxy, and aminoalkyl;

R^3 is independently selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, lower alkoxy, and lower aminoalkyl;

R^4 selected from the group consisting of hydrogen, halo, pseudohalo, cyano, nitro, hydroxyl, formyl, mercapto, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, $-R^{12}-OR^{13}$, $-R^{12}-N(R^{14})R^{15}$, $-R^{12}-C(O)R^{13}$, $-R^{12}-C(O)OR^{15}$, $-R^{12}-C(O)N(R^{14})R^{15}$, $-R^{12}-N(R^{14})C(O)R^{15}$, $-R^{12}-S(O)_tR^{15}$;

each R^5 independently selected from the group consisting of halo, cyano, nitro, hydroxyl, formyl, hydroxycarbonyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, $-OR^{20}$, $-S(O)_tR^{20}$, $-N(R^7)R^{20}$, $-C(O)R^{20}$, and $-C(O)OR^{20}$;

R^7 and R^9 are each independently H or optionally substituted alkyl;

R^{12} represents a C_1 - C_6 alkyl, C_1 - C_6 alkenyl, C_1 - C_6 alkynyl or C_1 - C_6 alkoxy;

R^{13} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{14} represents H or optionally substituted alkyl;

R^{15} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R^{20} represents optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl, and where each t is independently 0 to 2.

5 11. The pharmaceutical composition of any of claims 1-10 wherein each t is independently 0 or 2.

12. The pharmaceutical composition of any of claims 1-11 wherein the substituents, when substituted, are independently substituted with a group selected from Q^1 , wherein Q^1
 10 represents alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cyano, nitro, halo, hydroxyl, hydroxycarbonyl, pseudohalo, $-R^{30}-OR^{31}$, $-R^{30}-SR^{16}$, $-R^{30}-N(R^{32})(R^{33})$, $-R^{30}-C(J)R^{34}$, $-R^{30}-C(J)OR^{31}$, $-R^{30}-C(J)N(R^{32})(R^{33})$, $-R^{30}-C(J)N(R^{31})N(R^{32})(R^{33})$, $-R^{30}-N(R^{31})C(J)R^{34}$, $-R^{30}-N(R^{31})C(J)OR^{31}$, $-R^{30}-N(R^{31})C(J)N(R^{32})(R^{33})$, $-R^{30}-OC(J)R^{34}$, $-R^{30}-OC(J)OR^{31}$, $-R^{30}-OC(J)N(R^{32})(R^{33})$,
 15 $-Si(R^{35})_3$, $-N(R^{31})S(O)_yR^{36}$ or $-R^{30}-S(O)_yR^{36}$;

where each R^{30} is independently a direct bond or a straight or branched alkylene chain;

R^{31} and R^{34} are each independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoalkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;

R^{32} and R^{33} are each independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoalkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;

or R^{32} and R^{33} together with the nitrogen atom to which they are attached, form a heterocyclyl, heterocyclylalkenyl, or heteroaryl;

R^{35} , R^{36} and R^{16} are each independently alkyl, alkenyl, alkynyl, haloalkyl, alkoalkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;

each J is independently O or S; and each y is independently 0 to 2.

30 13. The pharmaceutical composition of any of claims 1-11 wherein the substituents, when substituted, are independently substituted with a group selected from Q^1 , wherein Q^1 represents alkyl, alkoxy, aminoalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cyano, nitro, halo, hydroxyl, hydroxycarbonyl or pseudohalo.
 35

14. A pharmaceutical composition comprising a compound selected from FIG. 1.

15. A method of altering the activity of a NGFI-B family member, or heterodimeric complex thereof by contacting said NGFI-B family member, or heterodimeric complex thereof with a compound or composition of claims 1-14.

5

16. The method of claim 15, wherein said NGFI-B family member is NGFI-B β , and said heterodimeric complex comprises NGFIB β and RXR.

10

17. A method for the treatment, prevention, or amelioration of one or more symptoms of a disease or disorder that is modulated by NGFI-B family activity, or in which NGFI-B family activity is implicated comprising administering any compound or composition of claims 1-14 to a patient in need of such treatment.

15

18. The method of claim 17, wherein said NGFI-B family activity is NGFI-B β or NGFIB β / RXR heterodimer activity.

20

19. The method of claim 17, wherein said disease or disorder is selected from Parkinson's disease, cancer, Alzheimer's disease, schizophrenia, manic depressive illness, multiple sclerosis, neuronal inflammatory responses, neuronal injury, stroke, neuronal degeneration, inflammation, acute inflammatory reactions, osteoporosis, arthritis, rheumatoid arthritis, psoriatic arthritis, sarcoid arthritis, osteoarthritis, ulcerative colitis, thyroiditis, atherosclerosis, and atherosclerosis related cardiovascular and coronary heart disease by administering a compound or composition of the present invention to patient in need of such treatment.

25

20. A method for regulating the activity of NGFI-B β / RXR heterodimers in neuronal cells in culture, comprising incubating a stem cell with any compound or composition of claims 1-14.

30

21. The method of claim 20, wherein said stem cell is an embryonic stem cell.

22. The method of claim 20, wherein said stem cell is derived from an adult.

35

23. A method for maintaining neuronal cell viability after a transplantation procedure comprising administering to a donor recipient any of the compounds or compositions of claims 1-14.

24. A method for the treatment, prevention, or amelioration of Parkinson's disease comprising administering to a patient in need thereof of one of the compounds or compositions of claims 1-14.

5

25. A method for the treatment, prevention, or amelioration of Alzheimer's disease comprising administering to a patient in need thereof of one of the compounds or compositions of claims 1-14.

10 26. A method for the treatment, prevention, or amelioration of multiple sclerosis comprising administering to a patient in need thereof of one of the compounds or compositions of claims 1-14.

15 27. A method for the treatment, or prevention of an inflammatory immune disease in a subject by administering to the subject in need of such treatment any one of the compounds or compositions of claims 1-14.

20 28. The method of claim 27, wherein said inflammatory disease is selected from arthritis, rheumatoid arthritis (RA); psoriatic arthritis, infectious arthritis, juvenile rheumatoid arthritis; osteoarthritis, and spondyloarthropaties.

25 29. A method for the treatment, prevention, or amelioration of a coronary heart disease event, a cerebrovascular event, and /or intermittent claudication in a subject by administering to the subject in need of such treatment any one of the compounds or compositions of claims 1-14.

30 30. A method for the treatment, prevention, or amelioration of osteoporosis in a subject by administering to the subject in need of such treatment any one of the compounds or compositions of claims 1-14.

31. A pharmaceutical composition comprising any one of the compounds or compositions of claims 1-14 and an additional active compound.

35 32. The pharmaceutical composition of claim 31, wherein said additional active compound is selected from levodopa (L-DOPA or L-dihydroxyphenylalanine), L-aromatic amino acid decarboxylase (AADC) inhibitors and catechol O-methyl transferase (COMT) inhibitors.

33. The pharmaceutical composition of claim 31, wherein said additional active compound is selected from an anti-inflammatory compound.

34. The pharmaceutical composition of claim 33, wherein said anti-inflammatory compound is selected from a matrix metalloproteinase inhibitor, an inhibitor of pro-inflammatory cytokines (e.g., anti-TNF molecules, TNF soluble receptors), non-steroidal anti-inflammatory drugs (NSAIDs), prostaglandin synthase inhibitors (e.g., choline magnesium salicylate, salicylsalicyclic acid), COX-1 or COX-2 inhibitors, (e.g. aspirin, acetaminophen, ibuprofen) or corticosteroids, (e.g. methylprednisone, prednisone, or cortisone).

35. The pharmaceutical composition of claim 31, wherein said additional active compound is selected from an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent, such as a cholesterol biosynthesis inhibitor, e.g., an hydroxymethylglutaryl (HMG) CoA reductase inhibitor (also referred to as statins, such as lovastatin, simvastatin, pravastatin, fluvastatin, and atorvastatin), an HMG-CoA synthase inhibitor, a squalene epoxidase inhibitor, or a squalene synthetase inhibitor (also known as squalene synthase inhibitor); an acyl-coenzyme A cholesterol acyltransferase (ACAT) inhibitor, such as melinamide; probucol; nicotinic acid and the salts thereof and niacinamide; a cholesterol absorption inhibitor, such as β -sitosterol; a bile acid sequestrant anion exchange resin, such as cholestyramine, colestipol or dialkylaminoalkyl derivatives of a cross-linked dextran; an LDL (low density lipoprotein) receptor inducer; fibrates, such as clofibrate, bezafibrate, fenofibrate, and gemfibrizol; vitamin B₆ (also known as pyridoxine) and the pharmaceutically acceptable salts thereof, such as the HCl salt; vitamin B₁₂ (also known as cyanocobalamin); vitamin B₃ (also known as nicotinic acid and niacinamide, supra); anti-oxidant vitamins, such as vitamin C and E and beta carotene; a beta-blocker; LXR α or β agonists, antagonists, or partial agonists, FXR agonists, antagonists, or partial agonists, an angiotensin II antagonist; an angiotensin converting enzyme inhibitor; and a platelet aggregation inhibitor, such as fibrinogen receptor antagonists (i.e., glycoprotein IIb/IIIa fibrinogen receptor antagonists) and aspirin.

36. The pharmaceutical composition of claim 31, wherein said additional active compound comprises parathyroid hormone (PTH) or physiologically active fragment thereof.